Targets › FTSZ
6 programs from 4 companies in 14 trials: 7 Phase 4, 4 Phase 1, 3 Phase 3; Other, Infectious disease, Oncology; next expected readout Dec 2026.
Open in Phaseline: the race on FTSZ, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Abdul El-Rabbany | Cefazolin Bacterial penicillin-binding protein inhibitor | FTSZ | Phase 4 | Orthognathic Surgical Site Infection | Jan 2027 |
| Uppsala University | Pivmecillinam Beta-lactam antibiotic that inhibits bacterial cell wall synthesis | FTSZ | Phase 4 | Febrile Urinary Tract Infection | Mar 2029 |
| Qilu Pharmaceutical | Meropenem Bacterial penicillin-binding protein inhibitor | FTSZ | Phase 3 | Hospital-acquired Bacterial Pneumonia (HABP); Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia; MDR Bacteria; Febrile Neutropenia … | Dec 2026 |
| Basilea Pharmaceutica | Ceftibuten Bacterial penicillin-binding protein inhibitor | FTSZ | Phase 1 | Healthy Volunteer | Dec 2026 |
| Basilea Pharmaceutica | Ceftibuten-ledaborbactam etzadroxil Beta-lactam antibiotic combined with beta-lactamase inhibitor | FTSZ | Phase 1 | Healthy Volunteer | Dec 2026 |
| Basilea Pharmaceutica | Ledaborbactam etzadroxil Beta-lactamase inhibitor | FTSZ | Phase 1 | Healthy Volunteer | Dec 2026 |
Sepsis (3) Healthy Volunteer (3) Hospital-acquired Bacterial Pneumonia (HABP) (1) Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia (1) MDR Bacteria (1) Febrile Neutropenia (1) Infection (1) Bloodstream Infection (1) Febrile Urinary Tract Infection (1) Orthognathic Surgical Site Infection (1)
small molecule (6)
Basilea Pharmaceutica (3) Qilu Pharmaceutical (1) Uppsala University (1) Abdul El-Rabbany (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.